tember 30, 2013 ResultsTotal operating expenses for the third quarter of 2013 were $65.5 million, compared with total operating expenses of $54.9 million for the comparable period in 2012.
Product revenue for the nine months ended September 30, 2013 was $192.1 million, compared with $173.5 million for the nine months ended September 30, 2012, an increase of 11 percent. Total revenue for the nine months ended September 30, 2013 was $192.8 million, compared with $174.7 million for the same period in 2012.
Net loss was $3.4 million for the nine months ended September 30, 2013, compared with net income of $6.3 million for the nine months ended September 30, 2012.
Cash and cash equivalents and short-term investments at September 30, 2013 were $114.0 million, compared with $99.1 million at December 31, 2012.
In the third quarter, more than 21,790 Oncotype DX test results were delivered, an increase of 21 percent, compared with more than 18,030 test results delivered in the same period in 2012.
Recent Business Highlights:Oncotype DX Commercial Progress
The National Institute for Health and Care Excellence (NICE) in the United Kingdom issued final guidance recommending Oncotype DX as the only multi-gene breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for patients with early-stage, hormone receptor-positive, invasive breast cancer.
Established node-positive and ductal carcinoma in situ (DCIS) coverage for approximately 1.3 million U.S. lives through a contract with a large Blue Cross Blue Shield state plan.
Medical Meeting Presentations, Publications and Pipeline
The Journal of Clinical Oncology accepted for publication positive results from the third successful validation of the Oncotype DX colon cancer test in patients with stage II disease and the first validation study in patients with stage III disease. Page: 1 2 3 4 5 6 7 8 Related medicine technology :1
. New MTHFR Gene Test Extends Holistic Pharmacogenomics Approach to Treating Depression2
. Genomic Health to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 20133
. Extensive Scientific Data Supports the Clinical Validity of Pharmacogenomic Testing for Predicting Patient Response to Psychiatric Medications4
. Life Technologies Ion Torrent Breakthrough Award Honors Discoveries and Genomic Research Fueled by Next-Generation Sequencing5
. BioNano Genomics Raises $10 Million Financing To Advance Irys System For Human Genome Analysis6
. Global Genomics Group (G3) and Illumina to Partner on Cardiovascular Genomics7
. S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poors Factual Stock Reports8
. Genomics and Proteomics Reagents, Research Kits and Analytical Instruments Market is Expected to Grow to USD 52.3 Billion Globally by 2019: Transparency Market Research9
. Quest Diagnostics Introduces Comprehensive Opioid Therapy Genetic Test Based on CYP450 Biomarker License with Transgenomic10
. Genomic Health to Present at the Canaccord Genuity 33rd Annual Growth Conference11
. Genomic Health Announces Second Quarter 2013 Financial Results and Business Progress